Document is current
Any future updates will be listed below
-
Authors
Vaziri-Gohar, Ali http://orcid.org/0000-0002-6924-8691
Hue, Jonathan J.
Abbas, Ata http://orcid.org/0000-0001-8272-1853
Graor, Hallie J.
Hajihassani, Omid
Zarei, Mehrdad http://orcid.org/0000-0003-0127-1489
Titomihelakis, George
Feczko, John
Rathore, Moeez
Chelstowska, Sylwia
Loftus, Alexander W.
Wang, Rui
Zarei, Mahsa
Goudarzi, Maryam http://orcid.org/0000-0003-4961-3935
Zhang, Renliang
Willard, Belinda
Zhang, Li
Kresak, Adam
Willis, Joseph E.
Wang, Gi-Ming
Tatsuoka, Curtis
Salvino, Joseph M. http://orcid.org/0000-0002-2184-5980
Bederman, Ilya
Brunengraber, Henri
Lyssiotis, Costas A.
Brody, Jonathan R.
Winter, Jordan M. http://orcid.org/0000-0002-5200-6557
-
Funding
Funding for this research was provided by:
University Hospitals research start-up package
Loyola University Chicago research start-up package
- License Information
-
More Information
Article History
Received: 5 May 2022
Accepted: 10 May 2023
First Online: 28 June 2023
Competing interests
: J.M.S. is a co-author on patents of IDH1 inhibitors, and has received sponsored research funding from the Barer Institute and patents pending to Wistar Institute. C.A.L. has received consulting fees from Astellas Pharmaceuticals and Odyssey Therapeutics, and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in cancer, and targeting the GOT1-pathway as a therapeutic approach. J.M.W. along with University Hospitals filed the following patent application on September 24, 2020: Methods for Treating Wild Type Isocitrate Dehydrogenase 1 Cancers. Information regarding this patent application is as follows: PCT/US20/52445 filed 09/24/20, Claiming Priority to US 62/911,717 filed 10/7/19, File Nos: UHOSP-19738 | 2019-014.
